Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CINDY E OWEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1598803819
CMS profile
117868
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$4,329.13

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,900.00 2
Food and Beverage $429.13 24

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CINDY E OWEN

NPI 1598803819 · CMS profile ID 117868

Allopathic & Osteopathic Physicians / Dermatology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1598803819?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $4,329.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $17.3811/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051267 CMS
Novartis Pharmaceuticals Corporation $14.6311/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051273 CMS
Novartis Pharmaceuticals Corporation $11.8010/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051255 CMS
Janssen Biotech, Inc. $11.4710/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719084959 CMS
Novartis Pharmaceuticals Corporation $11.5010/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051263 CMS
PFIZER INC. $3,600.0009/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743317927 CMS
GENZYME CORPORATION $13.3708/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744255765 CMS
Lilly USA, LLC $16.1708/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728387971 CMS
Regeneron Healthcare Solutions, Inc. $12.8907/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724443959 CMS
Amgen Inc. $24.1807/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741377171 CMS
AbbVie Inc. $15.7907/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722062811 CMS
AbbVie Inc. $23.2806/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722062809 CMS
Novartis Pharmaceuticals Corporation $16.9106/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051247 CMS
Regeneron Healthcare Solutions, Inc. $24.6006/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724443955 CMS
Amgen Inc. $15.4705/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741377173 CMS
Janssen Biotech, Inc. $23.2805/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719084957 CMS
PFIZER INC. $300.0003/16/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743135373 CMS
ORGANOGENESIS INC. $17.5103/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750620467 CMS
Amgen Inc. $27.0003/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741377169 CMS
UCB, Inc. $20.3402/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746112561 CMS
AbbVie Inc. $19.2102/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722062807 CMS
Novartis Pharmaceuticals Corporation $12.5602/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051243 CMS
Sun Pharmaceutical Industries Inc. $24.2702/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728261251 CMS
Amgen Inc. $18.8602/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741377167 CMS
Mission Pharmacal Company $23.4602/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 712453567 CMS
Novartis Pharmaceuticals Corporation $13.2001/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726051235 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,410.66 70
PY2020 $4,329.13 26
PY2021 $1,014.27 67
PY2022 $1,019.13 72
PY2023 $883.07 50
PY2024 $1,269.36 78
PY2025 $1,140.98 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $848,779.58 205
PY2024 Principal investigator $465,404.25 284
PY2023 Principal investigator $512,761.61 145
PY2022 Recipient $8.00 1
PY2022 Principal investigator $318,333.10 76
PY2021 Recipient $579.11 2
PY2021 Principal investigator $303,603.63 109
PY2020 Recipient $5,811.05 7
PY2020 Principal investigator $509,738.55 72
PY2019 Recipient $47,562.83 13
PY2019 Principal investigator $1,244,974.63 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

111 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $1,797.00 12/22/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 819463779
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $1,600.56 11/23/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902163
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $12,033.45 10/21/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902161
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $11.00 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902067
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $188.16 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902069
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $134.58 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902071
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $197.40 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902073
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $191.40 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902075
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $134.58 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902171
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $134.58 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902173
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $191.40 10/14/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902175
Principal investigator 1 Bausch Health US, LLC $18,854.36 09/17/2021 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850488299
Principal investigator 1 Bausch Health US, LLC $300.00 09/10/2021 Non-covered Recipient Entity
DS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850488241
Principal investigator 1 PFIZER INC. $13,057.50 08/20/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 832694995
Principal investigator 1 Bausch Health US, LLC $3,500.00 08/06/2021 Non-covered Recipient Entity
DS RESEARCH
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850488269
Principal investigator 1 PFIZER INC. $826.80 08/05/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832816463
Principal investigator 1 Incyte Corporation $15,317.22 08/02/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141857
Principal investigator 1 PFIZER INC. $826.80 07/20/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832870999
Principal investigator 1 PFIZER INC. $1,866.80 07/08/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832760579
Principal investigator 1 Incyte Corporation $2,472.30 07/06/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141805
Principal investigator 1 Incyte Corporation $64.80 07/06/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141811
Principal investigator 1 Bausch Health US, LLC $1,000.00 07/02/2021 Non-covered Recipient Entity
DS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850488185
Principal investigator 1 Bausch Health US, LLC $8,271.00 07/02/2021 Non-covered Recipient Entity
DS RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850488213
Principal investigator 1 PFIZER INC. $1,866.80 06/22/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832776673
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.50 06/17/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902065
Principal investigator 1 PFIZER INC. $5,168.80 06/04/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832723115
Principal investigator 1 PFIZER INC. $1,498.90 05/21/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832826456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,976.83 05/17/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY INVESTIGATING THE EFFICACY, SAFETY, AND PHARMACOKINETIC PROFILES OF REGN3500 ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 793102391
Principal investigator 1 PFIZER INC. $2,653.30 05/07/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832854949
Principal investigator 1 Incyte Corporation $700.00 05/04/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141715
Principal investigator 1 Incyte Corporation $5,625.00 05/03/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141709
Principal investigator 1 Amgen Inc. $275.00 04/30/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 830984997
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
ELITE CLINICAL TRIALS LLLP
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 819458627
Principal investigator 1 PFIZER INC. $3,714.10 04/21/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832891185
Principal investigator 1 Eli Lilly and Company $16.74 04/16/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819467127
Principal investigator 1 Eli Lilly and Company $15.30 04/08/2021 Non-covered Recipient Entity
CINCINNATI RHEUMATIC DISEASE STUDY GROUP INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819454985
Principal investigator 1 Eli Lilly and Company $7.65 04/08/2021 Non-covered Recipient Entity
JULIE B SCHWARTZBARD MD PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819458595
Principal investigator 1 Eli Lilly and Company $93.90 04/08/2021 Non-covered Recipient Entity
ROCHESTER CLINICAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819463389
Principal investigator 1 PFIZER INC. $3,126.50 04/08/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832915375
Principal investigator 1 PFIZER INC. $13,691.60 03/23/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832733885
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.08 03/18/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902039
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $255.20 03/18/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902041
Principal investigator 1 Eli Lilly and Company $137.25 03/08/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819456985
Principal investigator 1 PFIZER INC. $1,060.80 03/04/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832771171
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $50.00 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902043
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $35.00 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902045
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $6.25 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902047
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $58.00 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902049
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $0.75 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902051
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $12.50 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902053
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $2.40 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902055
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $19.20 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902057
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $8.50 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902059
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $2,495.00 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902063
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $2.40 03/02/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902169
Principal investigator 1 Genentech, Inc. $356.30 02/26/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
PHII OF MSTT1041A IN MOD SEVERE ATOPIC DERMATITITS No dispute reported 06/30/2026 836018315
Principal investigator 1 Eli Lilly and Company $554.89 02/23/2021 Non-covered Recipient Entity
SADICK RESEARCH GROUP LLC
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 819465409
Principal investigator 1 Eli Lilly and Company $10,148.00 02/23/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819466811
Principal investigator 1 Novartis Pharmaceuticals Corporation $399.00 02/23/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 800644485
Principal investigator 1 PFIZER INC. $8,166.60 02/23/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832881423
Principal investigator 1 Amgen Inc. $7,947.00 02/20/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 830984995
Principal investigator 1 ABBVIE INC. $497.00 02/16/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 792423533
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $68.00 02/12/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902029
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $12.00 02/12/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902031
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $40.00 02/12/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902033
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $7.50 02/12/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902035
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $10.00 02/12/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902037
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $575.00 02/12/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902061
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $50.00 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902009
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $35.00 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902011
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $6.25 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902013
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $58.00 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902015
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $250.00 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902017
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $0.75 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902019
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $12.50 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902021
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $2.40 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902023
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $84.00 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902025
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $80.00 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902027
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $0.75 02/11/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902167
Principal investigator 1 Eli Lilly and Company $42,484.50 02/09/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 819466809
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $204.00 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901981
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.00 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901983
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $22.00 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901987
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $564.48 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901989
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $134.58 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901991
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $107.16 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901993
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $658.00 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901995
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $382.80 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901997
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901999
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $24.69 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902001
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $441.00 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902003
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $29.52 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902005
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $88.20 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902007
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 02/04/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852902165
Principal investigator 1 PFIZER INC. $3,653.00 02/04/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832741847
Principal investigator 1 PFIZER INC. $1,500.00 02/04/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 832786709
Principal investigator 1 Genentech, Inc. $456.00 02/02/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
PHII OF MSTT1041A IN MOD SEVERE ATOPIC DERMATITITS No dispute reported 06/30/2026 836018309
Recipient Eli Lilly and Company $362.00 01/29/2021 Covered Recipient Physician A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 819444095
Principal investigator 1 PFIZER INC. $1,797.00 01/28/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO ASSESS THE EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 CREAM APPLIED ONCE OR TWICE DAILY FOR 6 WEEKS IN PARTICIPANTS WITH MILD OR MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 832703145
Recipient Eli Lilly and Company $217.11 01/26/2021 Covered Recipient Physician A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 819444837
Principal investigator 1 Eli Lilly and Company $590.56 01/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 819459095
Principal investigator 1 ABBVIE INC. $7,500.00 01/20/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy No dispute reported 06/30/2026 792410503
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,241.60 01/20/2021 Non-covered Recipient Entity
Rheumatology Associates Of North Alabama, P C
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 819899440
Principal investigator 1 PFIZER INC. $1,826.50 01/16/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832890297
Principal investigator 1 Incyte Corporation $943.38 01/12/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141607
Principal investigator 1 Eli Lilly and Company $598.50 01/11/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819459099
Principal investigator 1 PFIZER INC. $4,421.30 01/09/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 832804695
Principal investigator 1 PFIZER INC. $1,632.50 01/09/2021 Non-covered Recipient Entity
Scott Health Services LLC
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 832808351
Principal investigator 1 Eli Lilly and Company $22,672.00 01/05/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 819468351
Principal investigator 1 Eli Lilly and Company $51,077.00 01/05/2021 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 819468691
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $309.04 01/01/2021 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901979